# Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment

Source: https://onco.cc/trials/nct06617858/  
OnCo record `nct06617858` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by M.D. Anderson Cancer Center, now recruiting.

## Summary

Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment is a phase 2, interventional study registered as NCT06617858 by M.D. Anderson Cancer Center, with a registry enrolment figure of 15 participants, started 2024-12-04 and due to reach its primary completion in 2028-02-01. Interventions recorded: AMB-05X. Conditions listed: Colorectal Cancer. Primary outcome: Safety and Adverse Events (AEs). Colorectal eligibility wording from the registry: "Histologic or pathologic confirmation of adenocarcinoma of the colon or rectum". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06617858
- Phase: 2
- Setting: Open-label Phase 2 Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment
- Sponsor: M.D. Anderson Cancer Center
- Enrolled: 15

## Sources

- ClinicalTrials.gov NCT06617858: https://clinicaltrials.gov/study/NCT06617858

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06617858.json